Karla Solo1, Shahar Lavi2, Tawfiq Choudhury2, Janet Martin1,3, Immaculate F Nevis4, Chun Shing Kwok5, Rafail A Kotronias6, Natsumi Nishina7, Sandro Sponga8, Diana Ayan2, Nikolaos Tzemos, Mamas A Mamas5, Rodrigo Bagur1,2,5. 1. Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. 2. London Health Sciences Centre, London, Ontario, Canada. 3. Department of Anesthesia & Perioperative Medicine, Centre for Medical Evidence, Decision Integrity & Clinical Impact (MEDICI), Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. 4. Health Quality Ontario, Toronto, Ontario, Canada. 5. Keele Cardiovascular Research Group, Institute for Applied Clinical Science and Centre for Prognosis Research, Institute of Primary Care and Health Sciences, University of Keele, Stoke-on-Trent, UK. 6. Oxford University Clinical Academic Graduate School, Oxford University, Oxford, UK. 7. Faculty of International Communication, Gunma Prefectural Women's University, Tamamura, Gunma, Japan. 8. Cardiothoracic Department, University Hospital of Udine, Udine, Italy.
Abstract
Background: Aspirin therapy improves saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass graft (CABG), however, its use in the pre-operative period remains controversial. Therefore, we conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs) to update the evidence about risk and benefits of pre-operative aspirin therapy in patients undergoing CABG. Methods: Electronic databases (Medline, Embase, PubMed, Cochrane Library, and Scopus) were searched to identify RCTs evaluating the effect of aspirin versus placebo/control before CABG. Two investigators independently and in duplicate screened citations and extracted data and rated the risk of bias. The strength of evidence was appraised using the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. Meta-analysis was performed using a random-effects model. The main outcomes of interest were 30-day mortality, peri-operative myocardial infarction (MI), chest tube drainage and SVG occlusion. Results: A total of 13 RCTs involving 4,377 participants (2,266/2,111 pre-operative aspirin/control) met the inclusion criteria. Pre-operative aspirin reduced the risk of SVG occlusion [risk ratio (RR): 0.69, 95% confidence interval (CI): 0.49-0.97, P=0.03, I2=16%], but no differences in mortality (RR: 1.41, 95% Cl: 0.73-2.74, I2=0%) and MI (RR: 0.84, 95% CI: 0.69-1.03, I2=0%) were found. However, pre-operative aspirin increased chest tube drainage (MD: 100.40 mL, 95% CI: 24.32-176.47 mL, P=0.01, I2=84%) and surgical re-exploration (RR: 1.52, 95% CI: 1.02-2.27, P=0.04, I2=8%), with no significant difference in RBC transfusion (RR: 1.06, 95% CI: 0.90-1.25, I2=35%). Conclusions: Based on trials where the rated body of evidence was of low to very-low quality, pre-operative aspirin improves SVG patency but increases chest tube drainage and need for surgical re-exploration.
Background: Aspirin therapy improves saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass graft (CABG), however, its use in the pre-operative period remains controversial. Therefore, we conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs) to update the evidence about risk and benefits of pre-operative aspirin therapy in patients undergoing CABG. Methods: Electronic databases (Medline, Embase, PubMed, Cochrane Library, and Scopus) were searched to identify RCTs evaluating the effect of aspirin versus placebo/control before CABG. Two investigators independently and in duplicate screened citations and extracted data and rated the risk of bias. The strength of evidence was appraised using the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. Meta-analysis was performed using a random-effects model. The main outcomes of interest were 30-day mortality, peri-operative myocardial infarction (MI), chest tube drainage and SVG occlusion. Results: A total of 13 RCTs involving 4,377 participants (2,266/2,111 pre-operative aspirin/control) met the inclusion criteria. Pre-operative aspirin reduced the risk of SVG occlusion [risk ratio (RR): 0.69, 95% confidence interval (CI): 0.49-0.97, P=0.03, I2=16%], but no differences in mortality (RR: 1.41, 95% Cl: 0.73-2.74, I2=0%) and MI (RR: 0.84, 95% CI: 0.69-1.03, I2=0%) were found. However, pre-operative aspirin increased chest tube drainage (MD: 100.40 mL, 95% CI: 24.32-176.47 mL, P=0.01, I2=84%) and surgical re-exploration (RR: 1.52, 95% CI: 1.02-2.27, P=0.04, I2=8%), with no significant difference in RBC transfusion (RR: 1.06, 95% CI: 0.90-1.25, I2=35%). Conclusions: Based on trials where the rated body of evidence was of low to very-low quality, pre-operative aspirin improves SVG patency but increases chest tube drainage and need for surgical re-exploration.
Authors: S Goldman; J Copeland; T Moritz; W Henderson; K Zadina; T Ovitt; J Doherty; R Read; E Chesler; Y Sako Journal: Circulation Date: 1989-11 Impact factor: 29.690
Authors: Kevin A Bybee; Brian D Powell; Uma Valeti; A Gabriela Rosales; Stephen L Kopecky; Charles Mullany; R Scott Wright Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Alexander Kulik; Marc Ruel; Hani Jneid; T Bruce Ferguson; Loren F Hiratzka; John S Ikonomidis; Francisco Lopez-Jimenez; Sheila M McNallan; Mahesh Patel; Véronique L Roger; Frank W Sellke; Domenic A Sica; Lani Zimmerman Journal: Circulation Date: 2015-02-09 Impact factor: 29.690
Authors: L J Dacey; J J Munoz; E R Johnson; B J Leavitt; C T Maloney; J R Morton; E M Olmstead; J D Birkmeyer; G T O'Connor Journal: Ann Thorac Surg Date: 2000-12 Impact factor: 4.330
Authors: Abdul R Halabi; John H Alexander; Linda K Shaw; Todd J Lorenz; Lawrence Liao; David F Kong; Carmelo A Milano; Robert A Harrington; Peter K Smith Journal: Am J Cardiol Date: 2005-09-06 Impact factor: 2.778
Authors: Karla Solo; Shahar Lavi; Conrad Kabali; Glenn N Levine; Alexander Kulik; Ava A John-Baptiste; Stephen E Fremes; Janet Martin; John W Eikelboom; Marc Ruel; Ashlay A Huitema; Tawfiq Choudhury; Deepak L Bhatt; Nikolaos Tzemos; Mamas A Mamas; Rodrigo Bagur Journal: BMJ Date: 2019-10-10